Germany's Merck and GlaxoSmithKline have announced a global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult to treat cancers, in a deal worth up to 3.7 billion euros.
5th February 2019
MSD has announced that the US Food and Drug Administration (FDA) has accepted for review New Drug Applications (NDA) for two of its antibacterial agents.
5th February 2019
Roche has submitted a supplemental biologics license application in the US seeking to expand the use of Kadcyla to include the adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.
5th February 2019
AstraZeneca’s MEDI8897 has been granted access to both the European Medicines Agency (EMA) PRIME (PRIority MEdicines) scheme, and the US Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD).
5th February 2019
A Phase III trial of Sanofi's isatuximab’s has proven successful, showing that the drug achieved the primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
5th February 2019
Boots UK has announced plans to introduce a new specialist pharmacist practitioner role.
5th February 2019
The Royal Pharmaceutical Society (RPS) has published guidance on polypharmacy for pharmacists and all healthcare organisations involved with medicines.
5th February 2019
Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail, unveiling good news that more than half could be targeted by drugs currently already in trials for other cancer types.
5th February 2019
The US Food and Drug Administration (FDA) has rejected Alkermes' filing for ALKS 5461 in major depressive disorder (MDD), asking for more clinical data.
4th February 2019
Six medicines have taken a giant leap toward winning approval in Europe having won the backing of the European Medicines Agency’s (EMA) human medicines committee (CHMP).
4th February 2019
AstraZeneca’s Forxiga has been recommended by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) as an oral adjunct treatment to insulin in adults with type I diabetes.
4th February 2019
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer.
4th February 2019
GP practices in Gloucestershire are currently working together to provide 100,000 more appointments for patients.
4th February 2019
Havas Lynx stacked up an impressive eight Gold awards at the 33rd annual PM Society Awards in London on Friday, for exceptional work within the healthcare advertising and communications landscape.
3rd February 2019
Following its path as one of the most prestigious awards of its kind, this year’s PharmaTimes International Clinical Researcher of the Year competition has seen an incredible increase in entries and passes of more than 50% from 2018, and a 37% increase in essays submitted. It’s a good job we have such incredible, dedicated judges, with over 100 essays submitted in one category alone!
1st February 2019
